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Background: Oral medication for patients with type 2 diabetes mellitus plays an important role in diabetes care
and is associated with a high level self-care behavior and self-management. However, poor adherence to diabetes
treatment is common which causes severe health complications and increased mortality. Barriers to adherence may
consist of complex treatment regimens often along with long-term multi-therapies, side effects due to the medication
as well as insufficient, incomprehensible or confusing information or instructions provided by the health care provider.
Multidisciplinary approaches can support adherence success and can enable a more effective management of diabetes
care. One approach in diabetes care can be the involvement of a pharmacist. The aim was to analyze the effectiveness
of adherence-enhancing pharmacist interventions for oral medication in type 2 diabetes mellitus.
Methods: A systematic review of randomized controlled trials. The study quality was assessed with the Cochrane risk
of bias tool.
Results: Of 491 hits, six publications were included. Two studies mainly examining educational interventions showed a
significant improvement in adherence. Moreover, the quality of the included studies was deficient.
Conclusion: Although pharmacist interventions might potentially improve adherence to type 2 diabetes mellitus
medication, high-quality studies are needed to assess effectiveness.
Keywords: Adherence, Pharmacist intervention, Type 2 diabetes mellitus, Systematic reviewBackground
Oral medication for patients with type 2 diabetes mellitus
plays an important role in diabetes care and is associated
with a high level self-care behavior and self-management
[1]. However, poor adherence to diabetes treatment is com-
mon which causes severe health complications and in-
creased mortality [2-4]. This is reflected for instance by an
increase in the risk of cardiovascular diseases, neuropathy,
retinopathy, nephropathy and hospitalization rates [3,5,6].
Barriers to adherence may consist of complex treatment
regimens often along with long-term multi-therapies, side
effects due to the medication as well as insufficient, in-
comprehensible or confusing information or instructions
provided by the health care provider. Further barriers* Correspondence: Sunya-Lee.Antoine@uni-wh.de
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unless otherwise stated.challenging adherence could also be related to socioeco-
nomic issues, memory impairment, psychological well-
being and personal beliefs [5,7,8].
Multidisciplinary approaches can support adherence
success and can enable a more effective management of
diabetes care. Several models for diabetes care have been
developed and evaluated [9]. One approach in diabetes
care can be the involvement of a pharmacist, especially
since the role of a pharmacist has changed in the last
decades. As the training of pharmacists and their re-
sponsibilities include more than just the manufacturing
and administration of medicinal products, incorporating
pharmacists in the direct care of diabetic patients could
contribute to helping patients reach optimal adherence
[10-13]. The responsibilities of pharmacists involve for
example the long-term supervision, patient education
activities, the consideration of medication-related issues
(e.g. drug interactions) and of patient needs as well asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ence. Studies have shown that pharmacist interventions
positively influence health outcomes and patient satisfac-
tion, which are crucial indicators for quality of health care
and a key factor for medication adherence [11].
A previous systematic review examined the effects of
pharmacist interventions that improve adherence to oral
antidiabetic medications for type 2 diabetes mellitus
showing a positive effect on adherence [14]. However,
even though a search for educational, behavioral, affective
or provider-targeted strategies is described the provided
search strategy is restricted to certain search terms which
might lead to a non-identification of relevant publications.
Further, the identified studies included in the review are
merely described with respect to the study characteristics,
types of interventions and study results, but, they are not
systematically assessed for quality which impedes the
extensive and concluding appraisal of the respective inter-
ventions. Moreover, the review included cohort studies in
addition to randomized controlled trials aiming to provide
exhaustive and generalizable results. Nevertheless, the
consideration of non-randomized trials does not appear to
augment the value of the review with respect to further
outcome measures or longer follow-ups. Therefore, it was
sought to perform a systematic review on randomized
controlled trials analyzing the effectiveness of adherence-
enhancing interventions involving pharmacists for oral
medication in type 2 diabetes mellitus.
Methods
Literature search and selection criteria
A systematic search for relevant publications was con-
ducted in bibliographic databases (Medline via EMBASE,
EMBASE via EMBASE, CENTRAL via Cochrane Library)
in March, 2013. A search strategy for each database was
developed using medical subject headings and key words
for adherence, pharmacist interventions and type 2 dia-
betes mellitus. The full search strategies are provided in
Additional file 1. Randomized controlled/cluster-randomized
controlled trials as full-text publications investigating
pharmacist interventions in which a pharmacist is in-
volved in the provision of the intervention to improve
adherence, defined as the degree to which a patient fol-
lows the medical prescription in terms of interval and
dose of a dosing regimen [15], to oral medication in type
2 diabetes mellitus were eligible for inclusion. If the type
2 diabetes mellitus medication could not be clearly classi-
fied as oral medication (e.g. metformin, alpha-glucosidase
inhibitors, thiazolidinediones) the study was excluded.
Moreover, the examined population had to consist of adult
patients (≥18 years) and adherence to the oral medication
in type 2 diabetes mellitus had to be measured. No limi-
tation regarding the language or publication year of the
studies was made.Study selection
Two independent reviewers screened the titles and ab-
stracts of the identified publications according to the
pre-defined criteria. After obtaining the full-texts of the
potentially relevant publications two independent reviewers
screened them and determined their eligibility for further
analysis. If discrepancies regarding study inclusion could
not be solved by discussion a third reviewer was involved.
Data extraction
The results and study characteristics of each included
study were then extracted and a second reviewer checked
for accuracy and completeness. For this, standardized ta-
bles were used. These contained information on the first
author, the publication year, the study type, the country
and setting the trial took place, the study population size,
age and sex as well as the content and length of the inter-
vention and control intervention, the definition of adher-
ence, the adherence measures and the adherence rate at
baseline and last follow-up.
Risk of bias
The risk of bias in the included studies was assessed by
two independent reviewers according to pre-defined cri-
teria based on the Cochrane risk of bias tool [16]. How-
ever, the criteria related to blinding of participants and
personnel were not applicable. In adherence-enhancing
interventions participants and the personnel delivering
the intervention cannot be blinded due to the nature of
the interventions. Thus, the respective criteria were not
considered. Consequently, the criteria implemented to
assess the methodological quality of the included studies
consisted of questions related to the random sequence
generation, the allocation concealment, blinding of out-
come assessment, the analysis according to intention-to-
treat, selective reporting and other sources of bias. If
discrepancies regarding quality assessment could not be
solved by discussion a third reviewer was involved. It
was decided to rate each risk of bias item only as “yes”
and “no” and not as “unclear” as recent research sug-
gests that rating as “unclear” “becomes the default for
the risk of bias tool assessments (RoB) regarding reliabil-
ity” [17]. Moreover, it could be shown that a “significant
difference in effect sizes […} between studies with a high
or unclear risk of bias and those with a low risk of bias”
exists [18].
Results
The literature search yielded a total of 491 articles
(Figure 1). After screening titles and abstracts, 23 publica-
tions were considered as potentially relevant for further
screening [9,19-40]. Of these, two publications were not
obtainable and hence excluded. Eight studies were excluded
mainly due to the missing measurement of adherence.
Figure 1 Flow diagram of study selection.
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pharmacist was actively involved in the provision of
adherence-enhancing strategies for oral type 2 diabetes
mellitus medication. In one study the examined study
population were not adults (≥18 years), in one study the
type 2 diabetes mellitus medication was not an oral
medication and one study was not a randomized con-
trolled trial. In total, six publications met the selection
criteria and were included for further analysis [9,19-23].
The included studies showed qualitative deficits in
terms of risk of bias (Table 1). In most studies the allo-
cation sequence was not sufficiently generated (n = 4) as
well as concealed (n = 5), potentially causing a selection
bias. Further, the blinding of outcome assessment was
not reported in five of the included studies and an ana-
lysis according to intention-to-treat was described in half
of the included studies. In two studies a potential risk
for selective reporting and other sources of bias could be
identified. These are further depicted in the following
for each study when describing the results.
Among the included randomized controlled trials one
study was a cluster-randomized controlled trial in which
the participating pharmacists were randomly assigned to
the intervention or control group [9]. The investigated
interventions consisted of educational interventions sup-
porting the correct medication use as well as reminders
and counseling interventions, provided by pharmacists
in cooperation with the treating physician in different
settings and countries, e.g. outpatient health care facil-
ities, pharmacies and hospital settings (Table 2).In five studies [9,19-21,23] educational interventions
(e.g. by telephone or as group activities) addressing
topics such as disease, medication, diet, and lifestyle
modification were evaluated. In three of these studies
educational interventions were provided in addition to
social services and nutrition consultation as well as re-
minders about annual eye and foot examinations, indi-
vidual follow-up attendances, scheduled meetings with a
pharmacist and/or usual care [9,20,21]. One study inves-
tigated the implementation of a Diabetes Care Plan in
addition to weekly in-person or telephone meetings and
monthly follow-up phone calls [22]. Most interventions
were compared with usual care [9,21-23] whereas Adepu
et al. and Grant et al. used a cut-down provision of edu-
cational interventions as the comparator [19,20]. The
duration and intervals of the interventions varied across
all studies (from three to 36 months and from every
30 days to every 6 months).
In four of the studies adherence was defined as the
proportion of medication taken [9,21-23], in one study
the average change in adherence and in one study the
average change of the amount of missed medication in
the last 7 days were measured [19,20]. Self-reported ad-
herence was used in almost all studies to measure adher-
ence [9,19-21,23]. The prescription refill rate [9], the
periodicity of prescription pickups [21] were used in
addition in two studies and pill count was used to meas-
ure adherence by Phumipamorn [23]. Detailed informa-
tion on country, setting, population size as well as age
and sex can be found in Table 2.













Random generation of allocation sequence - - + - - +
Allocation concealment - - + - - -
Blinding of outcome assessment - - - + - -
Analysis according to intention-to-treat - - + + + -
Selective reporting - - + - + -
Other sources of bias + - + - - -
+ fulfilled, - not fulfilled.
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for improving adherence to type 2 diabetes mellitus me-
dication was reported, however, a statistically significant
effect was shown in only the studies by Odegard et al.
(p = 0.003) and Phumipamorn et al. (p = 0.004) (Table 2)
[9,19-23]. Odegard et al. investigated a Diabetes Care Plan
combined with weekly in-person and/or telephone meet-
ings and monthly follow-up telephone calls provided by
pharmacists against usual care [22]. They found that the
adherence in the intervention group was significantly
higher than in the control group, however, no adherence
rates were reported [22]. Phumipamorn et al. demon-
strated that the provision of scheduled meetings with a
pharmacist alongside with the physician’s appointment in-
creased adherence significantly compared with usual care.
Adepu et al. showed that education provided regularly (at
baseline and every 30 days for a duration of three months)
compared to just one education session (at month three)
tended to improve adherence [19]. However, the adher-
ence between intervention and control group differed
considerably at baseline, in spite of the fact that the study
was a randomized controlled trial. It was not reported
whether the differences at baseline were adjusted for in
their analysis. The educational telephone interviews in
addition to social services and nutrition consultations pro-
vided and arranged by a pharmacist examined by Grant
et al. reduced the amount of missed medication. Though,
the control group receiving only the educational telephone
interviews showed also an almost perfect adherence in
both groups at final measurement [20]. In the cluster-
randomized trial by Mehuys et al. higher adherence to an-
tidiabetic medication in the intervention group receiving
education and reminders about annual eye and foot exam-
inations compared to usual care in the control group was
reported. But the baseline adherence of the intervention
and control group was not reported. In addition, the pos-
sibility of cluster effects and the significance of the study
results were not described. Further, in this study all pa-
tients with an adherence of >100% were excluded from
the analysis [9]. Usual care complemented by a phar-
maceutical care intervention consisting of individual
follow-up attendances and educative group activities wascompared to usual care by Obreli-Neto et al. and appeared
to improve adherence, but no statistically significant effect
was described [21,23].
Discussion
The performed systematic review searched and analyzed
randomized controlled trials on pharmacist interven-
tions for patients taking oral type 2 diabetes medication
with respect to adherence. In all six included studies the
effect direction was in favor of the pharmacist interven-
tions on improving adherence to antidiabetic medica-
tion. Overall, of the six included studies two studies
showed a statistically significant effect of a Diabetes Care
Plan combined with weekly in-person and/or telephone
meetings and monthly follow-up telephone calls provided
by pharmacists and of a pharmaceutical care intervention
consisting of the provision of scheduled meetings with a
pharmacist alongside with the physician’s appointment
compared with usual care [22,23].
However, the included studies contain in parts hetero-
geneous interventions as well as different methods to
define, to operationalize and to measure adherence only
allowing for a comparison to a limited extent. In five
studies [9,19-21,23] educational interventions (e.g. by
telephone or as group activities) addressing topics such
as disease, medication, diet, and lifestyle modification
were evaluated. In three of these studies educational in-
terventions were provided in addition to social services
and nutrition consultation as well as reminders about
annual eye and foot examinations, individual follow-up
attendances, scheduled meetings with a pharmacist and/
or usual care [9,20,21]. Most interventions were com-
pared with usual care [9,21-23] whereas Adepu et al.
and Grant et al. used a cut-down provision of educa-
tional interventions as the comparator [19,20]. In
addition, as mentioned, self-reported adherence as well
as the prescription refill rate, the periodicity of prescrip-
tion pickups and pill count were mainly implemented as
the adherence measure in the included studies. Al-
though these represent adherence measures commonly
implemented, they might be subjected to overestimation
of adherence [41,42].
Table 2 Study results
Author,
Year
Adepu (2010) [19] Grant (2003) [20] Mehuys (2011) [9] Obreli-Neto (2011) [21] Odegard (2005) [22] Phumipamorn
(2008) [23]


















n = 227 62/58 153/135 97/97 39/27 63/67
Age (IG/CG) >57 64 ± 12/69 ± 10 62 (45-79)/63 (40-84) 65 ± 5.8/65 ± 5.7 52 ± 11.6/52 ± 10.4 52 ± 11.15/56 ± 13.67
Sex (IG/CG) 49% female 55%/69% female 54%/51% male 63%/62% female 48%/48% female 92%/76% female
Intervention Education (Baseline,
every 30 days for a






Education & Reminders about
annual eye and foot
examinations (Baseline, at each
prescription refill visit for a
period of 6 months)
Usual care + individual
follow-up attendances & edu-
cative group activities (every
6 months for period of
36 months)
Diabetes care plan DCP) & Weekly in
person/telephone meetings & monthly
follow-up phone calls (6-month intervention,
follow-up at month 6 and 12)
Usual care & 4
scheduled meetings
with a pharmacist
(every 2 months) &
education
Control Education (month 3) Educational telephone
interview







last 7 days (change
from baseline)













Self-reported adherence Pill count
Adherence
(IG/CG)
Baseline 0.73/1.11 6.7/6.9 NR 51/49 56/35 82/87
53/53
Final (%) 0.88/0.67 0.1/0.1 (change from
baseline)
99.7/94.7 (prescription refill rate) 84/44 (self-reported
adherence)
IG < CG 89/85
p = NR p = 0.8 p = NR 84/43 (periodicity of
prescription pickup)
p = 0.003 p = 0.004
61/62 (self-reported adherence) p = NR
p = NR
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cluded studies measured in addition relevant clinical out-
comes such as blood glucose and blood pressure values as
their reduction and maintenance are key aims in diabetes
care to prevent possible complications and to achieve
health gains in diabetic patients [34]. Statistically significant
changes in blood pressure and blood glucose levels were
found in favor of the intervention groups receiving phar-
maceutical care in the majority of the studies [9,19,21-23].
Other relevant outcomes such as knowledge and self-
management as factors affecting adherence were also
assessed. The involvement of a pharmacist contributed
to an improvement of knowledge and self-care activities in
three studies [9,19,23]. However, different instruments
were used for the assessment and knowledge as well as
self-management values at the baseline and final assess-
ment varied within and between the study groups among
the studies. Moreover, the sample size was not adequately
calculated in almost all of the studies or the sample size
calculation was not reported [9,19-22].
A possible limitation is that pharmacists might indi-
vidually differ in the way they provide their adherence-
enhancing intervention. Additionally, they might show
differences in identifying individual medication-related
issues and patient needs, the intensity of the pharmacist-
patient contact as well as in education and communica-
tion skills causing variances in outcomes. This issue has
also been noted in other related publications [43,44].
Moreover, an aspect to be considered is the fact that
pharmacists in their respective health care systems, in
which the studies were conducted, are differently inte-
grated in the health care provision [45]. For instance, in
some health care systems pharmacist care might be
more established and integrated as an organized element
in the management of diseases as in other health care
systems. Aspects such as education, professionalization,
recognition and reimbursement just to mention some
are essential influencing factors related to the differences
in pharmacy care [46,47]. The differences in the role of
pharmacists in different countries contribute to the diffi-
culty in comparing the different pharmacist interven-
tions. Hence, making a generalized conclusion remains
difficult, especially against the background that the ana-
lyzed randomized controlled trials are conducted in vari-
ous different countries with varying living circumstances
and cultural backgrounds.
We could not judge in how far the results of our qual-
ity assessment are in line with the quality assessment by
Omran et al. as their results are not depicted in detail.
In addition to the randomized controlled trials also iden-
tified by Omran et al. our review identified three further
relevant randomized controlled trials. Two studies by Al
Mazroui et al. and Skaer et al. [34,39] which were in-
cluded in the review by Omran et al. were not includedin our review as they either did not fulfill our inclusion
criteria or were not accessible.
The influence of pharmacist interventions in increas-
ing adherence has been demonstrated in several publica-
tions, showing that the results of our review are in line
with those of other publications, however, in how far
health outcomes, quality of life or cost-effectiveness are
improved is ambiguous [10,11,14,44,48]. Thus, further
studies of high quality are needed to assess significant
effectiveness of adherence-enhancing pharmacist inter-
ventions care, especially against the background that the
study quality of the included trials in this review are de-
ficient [14,49,50].
Conclusion
Our review shows the existing evidence on the effectiveness
of pharmacist interventions to enhance adherence in
patients suffering type 2 diabetes mellitus. The out-
comes of the analyzed studies indicate that pharmacists
could have an influential and important role in the re-
spective health care system to improve adherence in pa-
tients taking oral type 2 diabetes mellitus medication.
However, the heterogeneity of study populations inter-
ventions, adherence measures and outcomes in the in-
cluded studies prevents a comparison as well as a
generalization. Besides, our review points out the lack
of randomized controlled trials of pharmacist interven-
tions in oral type 2 diabetes mellitus medication. Never-
theless, pharmacists should be further considered as an
integral component in the health care provision for type
2 diabetes mellitus care, especially in terms of helping
patients to reduce non-adherence and hence to improve
health outcomes in patients taking oral type 2 diabetes
mellitus medication. Future randomized controlled tri-
als should be sought for to provide comparable results
of outcomes.
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